Drug Type Antibody drug conjugate (ADC) |
Synonyms TRO 02, TRO02 |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Small Cell Lung Cancer | Preclinical | South Korea | 01 May 2025 | |
| Triple Negative Breast Cancer | Preclinical | South Korea | 01 May 2025 |






